Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor Activator of Nuclear Factor Kappa Beta Ligand (RANKL)
- Target
- RANKL
- Molecular classification
- Type II transmembrane protein, Tumor Necrosis Factor (TNF) superfamily member, Cytokine, Ligand
01
Overview
Receptor activator of nuclear factor kappa beta ligand (RANKL) is a type II transmembrane protein and a member of the tumor necrosis factor (TNF) cytokine family. It plays a central role in bone metabolism, immune regulation, and several pathological processes by binding to its receptor RANK on osteoclast precursors, inducing their differentiation, activation, and survival. RANKL is also involved in immune system functions, including dendritic cell maturation and T cell regulation. Dysregulation of RANKL is implicated in osteoporosis, rheumatoid arthritis, and cancer, making it a therapeutic target for monoclonal antibodies.
- Other names
- TNFSF11TRANCEOPGLODF
02
Mechanism of action
Monoclonal antibodies bind to RANKL, preventing it from activating RANK and inhibiting osteoclast formation and bone resorption.
03
Biological functions
Bone metabolismOsteoclast differentiation and activationImmune regulationDendritic cell maturation and survivalT cell-dependent immune responsesLymph node development
04
Disease associations
OsteoporosisRheumatoid arthritisCancerSkeletal disordersBone loss
05
Safety considerations
Increased risk of infectionsHypocalcemiaOsteonecrosis of the jawAtypical femoral fractures
06
Interacting drugs
Monoclonal antibodies against RANKL (e.g., Denosumab)
Beyond the preview
Go deeper on Receptor Activator of Nuclear Factor Kappa Beta Ligand (RANKL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Receptor Activator of Nuclear Factor Kappa Beta Ligand (RANKL).